Osiris poised to lead stem cell drug market

12/27/2007 | Sun (Baltimore), The

Osiris Therapeutics may conquer the stem cell drug market in 2008, with clinical trials of its candidates showing promise. Three pivotal late-stage trials are under way to test intravenous drug Prochymal for Crohn's disease and graft-versus-host disease. The company also plans to conduct a Phase III trial for Chondrogen, which yielded positive results in midstage tests in treating knee pain caused by osteoarthritis.

View Full Article in:

Sun (Baltimore), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC